Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RABIDUX 10 MG/5 MG CAPSULAS DURAS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/RABIDUX 10 MG/5 MG CAPSULAS DURAS

Approved

STANDARD

RABIDUX 10 MG/5 MG CAPSULAS DURAS

Adamed Laboratorios S.L.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 11, 2022
Approval ID: f93163bbc927dd97
Company: Adamed Laboratorios S.L.U.
Type: Standard

Approval Details

Approval Id: f93163bbc927dd97
Drug Cima Aemps Name: RABIDUX 10 MG/5 MG CAPSULAS DURAS
Register Number: 87201
Holder Company Name: Adamed Laboratorios S.L.U.
Marketing Company Name: Adamed Laboratorios S.L.U.
Authorization Date: 2022-05-11
Dosage Form: CÁPSULA DURA
Dose: 10 mg/5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Adamed Laboratorios S.L.U.

Active Ingredients

RAMIPRIL

10 mg

BISOPROLOL FUMARATO

5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 11, 2022

Approval ID

f93163bbc927dd97

Type

Standard

Back to CIMA-AEMPS Approvals